$FOCL

Annen Steven purchased $24K of FOCL

Annen Steven (SVP, Marketing & Product Mgmt.) purchased 5,000 shares of EDAP TMS SA (FOCL) at $4.75 on 2026-08-14.

Original reporting
SEC EDGAR · Annen Steven
Published Aug 17, 2026, 10:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FOCL
Neutral
medium confidence
Mentioned
$FOCL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FOCLNeutralLow
01

Why it matters

A disclosed open-market purchase by a marketing and product management SVP may be interpreted as mild bullish sentiment, but it does not introduce new company performance or guidance information.

02

Market read

Traders may note the insider buy as a small sentiment datapoint, but it is unlikely to drive a sustained repricing without additional fundamentals.

03

What to watch

The filing does not provide a rationale for the purchase, and the transaction size may be small relative to typical trading volumes.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction report for EDAP TMS SA (FOCL).

Company-level read

Ticker impact

$FOCLNeutralMedium confidence
Context

EDAP TMS SA (FOCL) disclosed an insider open-market purchase by SVP Annen Steven of 5,000 shares at $4.75 on 2026-08-14.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

Form 4 insider purchases can be informative, but this is a single officer transaction with no stated 10b5-1 plan and no accompanying company-specific operational news.

Market effects

No sector read-through; this is an isolated insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity and may not reflect a change in company fundamentals.

Key entities

  • EDAP TMS SA

    Company subject of the Form 4 insider transaction disclosure.

  • Annen Steven

    SVP, Marketing & Product Mgmt. who purchased 5,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

$FOCLMed

FocalTherics Q2 Earnings Call Highlights

FocalTherics (NASDAQ:FOCL) reported Q2 highlights from its earnings call. U.S. Focal One procedure volumes rose 47% YoY. HIFU gross margin increased to 55.6% from 51.1%. Cash was $21.5M and it drew about €14M under its EIB credit facility. The company plans a $40M Aug. 14 offering and reiterated 2026 HIFU revenue guidance of $50M to $54M.

$FOCLMedAI 8/10

FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M

FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial resul

$FOCLMed

FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down

FocalTherics (FOCL) reported preliminary unaudited Q2 2026 results. Revenue is expected at $12.7 to $13.2 million, up 34% to 39% from $9.7 million in Q2 2025, with gross margin at 54% to 56% versus 42.5%. Cash and investments were $21.5 million as of June 30. The company priced a public offering of 8.425M ADS at $4.75 to raise about $40M gross, with an option for 1.26375M more ADS.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com